Diagnosing diffuse malignant mesothelioma (DMM) typically relies on tumor characteristics like structure and the presence of certain biomarkers. However, DMM is often hard to distinguish from other cancers of the lung and between its three subtypes: epithelioid, sarcomatoid and biphasic. To help ease the confusion, German researchers have developed a new tissue-sample imaging and collecting technique for DMM, according to Mesothelioma Research News. (more…)
Posts Tagged ‘malignant mesothelioma’
Mesothelioma Research News reports drug 5-aza-dC has been found in a recent study to reduce DNA methylation, a common gene “signaling tool that locks the genes in the ‘off’ position,” according to Nature Education, and could possibly “improve the effectiveness of anti-cancer drugs and reduce the most aggressive mesothelioma cells that are often associated with treatment resistance.” (more…)
A new study on malignant mesothelioma (MM) cells has revealed what could allow doctors the opportunity to diagnose and treat the deadly disease sooner than ever before.
According to a recent study published in “Scientific Reports,” malignant mesothelioma cells can secrete tiny vesicles comprising of several proteins, also known as exosomes, that educate the tumor’s microenvironment and cause the disease to develop further. While the proteins don’t necessarily provide a cure for malignant mesothelioma, they do provide scientists with crucial diagnostic markers, including targets for future therapeutic approaches. (more…)
A recent report published in blood, the Journal of the American Society of Hematology, is examining a possible increased risk for malignant mesothelioma among patients exposed to radiation treatment for Hodgkin lymphoma. According to the study, whose lead author is Marie L. DeBruin, increased risks for second primary mesothelioma after radiation for lymphoma have been reported. Mesothelioma is primarily related to asbestos exposure.
According to the journal summary, the findings are based on a small number of patients, so researchers are approaching these results with caution and anticipate more study to confirm the results. The team examined mesothelioma in 2,567 five-year survivors of Hodgkin lymphoma, who had been treated with radiation alone, chemotherapy alone, or a combination of the two.
The study indicated that mesothelioma risk was almost 30 times greater in Hodgkin lymphona patients treated with radiation than in the general population.
The journal article was summarized by HemOncToday, which reports clinical news in oncology and hematology. The publication says the median follow-up period for patients included in the radiation-mesothelioma study was 18.1 years, at which time researchers found 13 patients had malignant mesothelioma at least five years after being treated for Hodgkins lymphoma.
HemOncToday reports there were no cases of mesothelioma among patients treated with chemotherapy alone, but that patients treated with both radiation and chemotherapy were almost 44 times more likely to develop malignant mesothelioma.
Harry S. Jacob, MD, HemOncToday chief medical editor, provided this perspective:
“Seminal studies by Scripps Research Institute investigators demonstrated that asbestos with high-iron content (as opposed to low-Fe level asbestos) was more likely to cause mesotheliomas in miners. In vitro iron-asbestos promoted oxygen radical generation that altered DNA, providing rationale for the epidemiologic studies. The combination of radiation-mediated oxygen radicals plus lung iron asbestos (or tobacco-mediated iron deposition) may underlie these findings.”